12,492 Labcorp Holdings Inc. $LH Shares Sold by Russell Investments Group Ltd.

Russell Investments Group Ltd. trimmed its holdings in shares of Labcorp Holdings Inc. (NYSE:LH – Free Report) by 8.8% during the 3rd quarter, HoldingsChannel reports. The institutional investor owned 129,143 shares of the medical research company’s stock after selling 12,492 shares during the period. Russell Investments Group Ltd.’s holdings in Labcorp were worth $39,798,000 as of its most recent SEC filing.

Several other institutional investors also recently bought and sold shares of the stock. R Squared Ltd acquired a new position in Labcorp during the third quarter valued at approximately $305,000. Banyan Capital Management Inc. acquired a new stake in shares of Labcorp in the third quarter worth $11,755,000. Maryland State Retirement & Pension System lifted its stake in shares of Labcorp by 13.3% in the third quarter. Maryland State Retirement & Pension System now owns 5,092 shares of the medical research company’s stock worth $1,569,000 after buying an additional 596 shares during the last quarter. Illinois Municipal Retirement Fund lifted its stake in shares of Labcorp by 4.5% in the third quarter. Illinois Municipal Retirement Fund now owns 49,854 shares of the medical research company’s stock worth $15,361,000 after buying an additional 2,163 shares during the last quarter. Finally, Lido Advisors LLC boosted its holdings in shares of Labcorp by 365.0% during the 3rd quarter. Lido Advisors LLC now owns 4,673 shares of the medical research company’s stock worth $1,440,000 after buying an additional 3,668 shares during the period. 95.94% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

LH has been the topic of several recent analyst reports. Mizuho set a $355.00 target price on shares of Labcorp in a report on Monday, August 10th. UBS Group boosted their target price on shares of Labcorp from $380.00 to $420.00 and gave the stock a “buy” rating in a research report on Thursday, October 29th. Piper Sandler upped their price target on shares of Labcorp from $300.00 to $309.00 and gave the company a “neutral” rating in a report on Tuesday, August 4th. Morgan Stanley reaffirmed an “overweight” rating and issued a $388.00 price target on shares of Labcorp in a research report on Thursday, October 29th. Finally, Weiss Ratings upgraded Labcorp from a “buy (b+)” rating to a “buy (a-)” rating in a research note on Wednesday, October 21st. One investment analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating and three have given a Hold rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $369.08.

Check Out Our Latest Analysis on Labcorp

Insider Buying and Selling

In other Labcorp news, EVP Bryan T. Vaughn sold 306 shares of the business’s stock in a transaction on Tuesday, November 3rd. The shares were sold at an average price of $353.70, for a total value of $108,232.20. Following the sale, the executive vice president owned 6,845 shares of the company’s stock, valued at $2,421,076.50. The trade was a 4.28% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Brian J. Caveney sold 2,000 shares of the stock in a transaction on Tuesday, November 10th. The shares were sold at an average price of $372.04, for a total transaction of $744,080.00. Following the completion of the transaction, the executive vice president owned 34,562 shares of the company’s stock, valued at approximately $12,858,446.48. This represents a 5.47% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 3,384 shares of company stock valued at $1,241,707 over the last ninety days. 0.84% of the stock is owned by company insiders.

Labcorp Trading Up 0.5%

Labcorp stock opened at $372.38 on Tuesday. The business has a 50 day moving average price of $330.51 and a two-hundred day moving average price of $293.10. The company has a quick ratio of 1.22, a current ratio of 1.41 and a debt-to-equity ratio of 0.60. The stock has a market cap of $30.24 billion, a price-to-earnings ratio of 30.55, a price-to-earnings-growth ratio of 2.10 and a beta of 0.86. Labcorp Holdings Inc. has a 12 month low of $245.00 and a 12 month high of $375.10.

Labcorp (NYSE:LH – Get Free Report) last announced its quarterly earnings data on Wednesday, October 28th. The medical research company reported $4.78 EPS for the quarter, topping analysts’ consensus estimates of $4.64 by $0.14. Labcorp had a return on equity of 17.13% and a net margin of 6.88%. The company had revenue of $3.81 billion during the quarter, compared to the consensus estimate of $3.76 billion. During the same quarter last year, the company earned $4.18 EPS. The company’s quarterly revenue was up 6.9% on a year-over-year basis. As a group, equities analysts forecast that Labcorp Holdings Inc. will post 18.51 EPS for the current year.

Labcorp Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, December 11th. Investors of record on Tuesday, November 24th will be paid a $0.72 dividend. This represents a $2.88 dividend on an annualized basis and a dividend yield of 0.8%. The ex-dividend date is Tuesday, November 24th. Labcorp’s dividend payout ratio is presently 23.63%.

Labcorp Profile

(Free Report)

Labcorp (NYSE: LH), formally Laboratory Corporation of America Holdings, is a global life sciences company that provides diagnostic testing and services to patients, physicians, hospitals, employers and other health care organizations. Its offerings include routine and specialty laboratory tests, anatomic pathology and genetic testing. The company also supports pharmaceutical and biotechnology companies with laboratory services for drug development and clinical trials, including testing and analysis used in research and clinical studies.

Featured Stories

Want to see what other hedge funds are holding LH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Labcorp Holdings Inc. (NYSE:LH – Free Report).

Institutional Ownership by Quarter for Labcorp (NYSE:LH)

Receive News & Ratings for Labcorp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Labcorp and related companies with MarketBeat.com's FREE daily email newsletter.